IJCS | Volume 31, Nº4, Julho / Agosto 2018

442 41. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102-11. 42. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. 43. von Haehling S, Lainscak M, Kung T, Cramer L, Fülster S, Pelzer U, et al. Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. Arch Med Sci. 2013;9(2):261-7. 44. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53(2):121-9. 45. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13(5):797-801. 46. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonaki N, et al. Cardiotoxicity of fluoropyrimidines in different schedulesof administration: a prospective study. J Cancer Res ClinOncol. 2008;134(1):75-82. 47. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-73. 48. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testic ularcancer:a20-yearfollow-upstudy.JClinOncol. 2010;28(30):4649-57. 49. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-23. 50. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232-9. Erratum in: J Natl Cancer Inst. 2008;100(2):156, J Natl Cancer Inst. 2008;100(9):685. 51. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280-5. 52. Caponero R. Consenso Brasileiro de fadiga. Revista Brasileira de Cuidados Paliativos. 2010;3(2 supl 1):3-31. 53. Mota DD, Pimenta CA, Fitch MI. Fatigue Pictogram: an option for assessing fatigue severity and impact. Rev Esc Enferm USP. 2009;43(Spe):1079-86. 54. Mota DD, Pimenta CA, Piper BF. Fatigue in Brazilian cancer patients, caregivers, and nursing students: a psychometric validation study of the Piper Fatigue Scale-Revised. Support Care Cancer. 2009;17(6):645-52 55. Ishikawa NM, Thuler LC, Giglio AG, Baldotto CS, de Andrade CJ, Derchain SF, et al. Validation of the Portuguese version of Functional Assessment of Cancer Therapy-Fatigue (FACT-F) in Brazilian cancer patients. Support Care Cancer. 2010;18(4):481-90. Borges et al. Cardio-oncologia e sintoma fadiga Int J Cardiovasc Sci. 2018;31(4)433-442 Artigo de Revisão Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons